Regeneron Reports registry Data for Mepolizumab in Psoriatic arthritis

Regeneron today announced registry results for mepolizumab in patients with psoriatic arthritis. The study demonstrated that mepolizumab demonstrates safety and tolerability compared to standard of care or placebo. These results provide important insights into the treatment of psoriatic arthritis and support the continued development of mepolizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.